Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Omega-3 fatty acids and dyslipidemic agent for lipid therapy

A technology of dyslipidemia and fatty acid, applied in the field of omega-3 fatty acid and dyslipidemia agent for blood lipid treatment

Inactive Publication Date: 2008-01-02
RELIANT PHARMACEUTICALS INC
View PDF18 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0038] Combinations of omega-3 fatty acids with other fibrates such as gemfibrozil and clofibrate have not been shown to produce any unexpected synergistic effects in the treatment of hyperlipidemia and hyperlipoproteinemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0093] Omacor 4 grams per day has been reviewed  Effects of omega-3 fatty acids on lipid parameters, namely triglyceride levels (TG), total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL). The Omacor  Omega-3 fatty acids are provided in liquid-filled gel capsules for oral administration. Omacor per gram  The capsules contain at least 900 mg of ethyl esters of omega-3 fatty acids, mainly comprising eicosapentaenoic acid (EPA) (about 465 mg) and docosahexaenoic acid (DHA) (about 375 mg). As shown in Table 1, Omacor  The efficacy of omega-3 fatty acids depends on the baseline TG levels of the treated patients.

[0094] Table 1 Administration of Omacor  Percent change in lipid parameters in patients after monotherapy

[0095] baseline

TG (mg / dL)

TG

total cholesterol

HDL

LDL

VLDL

non-HDL

0-199

-22.5

3.5

5.2

10.7

-31.6

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method and composition for blood lipid therapy that comprises administering to the subject an effective amount of a PPAR agonist and / or antagonist and an omega-3 fatty acid. The methods and compositions include combination products or concomitant therapy for the treatment of subjects with hypertriglyceridemia, hypercholesteremia, mixed dyslipidemia, vascular disease, a rtheroscl erotic disease and related conditions, obesity, the prevention or reduction of cardiovascular and vascular events, the reduction of insulin resistance, fasting glucose levels and postprandial glucose levels, and / or the reduction of incidence and / or the delay of onset of diabetes.

Description

[0001] This application claims from Serial No. 60 / 633,125 filed December 6, 2004, Serial No. 60 / 659,099 filed March 8, 2005, and Serial No. 60 / Priority to provisional patent application 699,866. The disclosure of said provisional application is incorporated herein by reference. technical field [0002] The present invention relates to the treatment of patients with hypertriglyceridemia, coronary heart disease (CHD), vascular disease, arteriosclerosis ( arterosclerotic disease) and related conditions, and methods of preventing or reducing cardiovascular and vascular disease. Background technique [0003] In humans, cholesterol and triglycerides are part of lipoprotein complexes in the bloodstream that can be separated by ultracentrifugation into high-density lipoproteins (HDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL ) and very low-density lipoprotein (VLDL) fraction. Cholesterol and triglycerides are synthesized in the liver, combined into ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/225
CPCA61K31/202A61K31/192A61K31/426A61K31/22A61K45/06A61P3/04A61P3/06A61P3/08A61P3/10A61P9/00A61P9/10A61K2300/00
Inventor 鲁洛夫·M.·L.·龙根乔治·博博泰斯
Owner RELIANT PHARMACEUTICALS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com